ENDONOVO THERAPEUTICS, INC. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2011 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Endonovo Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2011 to Q3 2023.
  • Endonovo Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2023 was -$766K, a 27% decline year-over-year.
  • Endonovo Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2023 was -$4.4M, a 40% decline year-over-year.
  • Endonovo Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$18.5M, a 495% decline from 2021.
  • Endonovo Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$3.1M, a 685% decline from 2020.
  • Endonovo Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2020 was -$396K, a 97.7% increase from 2019.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2023 -$4.4M -$766K -$163K -27% Jul 1, 2023 Sep 30, 2023 10-Q/A 2023-12-29
Q2 2023 -$4.24M $2.06M +$4.59M Apr 1, 2023 Jun 30, 2023 10-Q/A 2023-12-29
Q1 2023 -$8.83M $7.23M +$9.64M Jan 1, 2023 Mar 31, 2023 10-Q/A 2023-12-29
Q4 2022 -$18.5M -$12.9M -$15.3M -640% Oct 1, 2022 Dec 31, 2022 10-K 2023-04-17
Q3 2022 -$3.15M -$603K +$920K +60.4% Jul 1, 2022 Sep 30, 2022 10-Q/A 2023-12-29
Q2 2022 -$4.07M -$2.53M -$1.23M -94.8% Apr 1, 2022 Jun 30, 2022 10-Q/A 2023-12-29
Q1 2022 -$2.84M -$2.41M +$268K +9.98% Jan 1, 2022 Mar 31, 2022 10-Q/A 2023-12-29
Q4 2021 -$3.1M $2.4M +$4.43M Oct 1, 2021 Dec 31, 2021 10-K 2023-04-17
Q3 2021 -$7.53M -$1.52M -$455K -42.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-21
Q2 2021 -$7.08M -$1.3M +$338K +20.7% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-21
Q1 2021 -$7.41M -$2.68M -$7.02M -162% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-21
Q4 2020 -$396K -$2.03M +$3.63M +64.2% Oct 1, 2020 Dec 31, 2020 10-K 2022-04-14
Q3 2020 -$4.03M -$1.07M +$337K +24% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-19
Q2 2020 -$4.37M -$1.63M +$6.2M +79.1% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-19
Q1 2020 -$10.6M $4.34M +$6.74M Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-19
Q4 2019 -$17.3M -$5.66M -$7.05M -510% Oct 1, 2019 Dec 31, 2019 10-K 2021-04-13
Q3 2019 -$10.3M -$1.41M +$4.54M +76.4% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-19
Q2 2019 -$14.8M -$7.84M -$6.59M -527% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-19
Q1 2019 -$8.22M -$2.41M -$1.79M -289% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-19
Q4 2018 -$6.44M $1.38M -$387K -21.9% Oct 1, 2018 Dec 31, 2018 10-K 2020-05-04
Q3 2018 -$6.05M -$5.95M +$724K +10.9% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-19
Q2 2018 -$6.77M -$1.25M -$3.11M -167% Apr 1, 2018 Jun 30, 2018 10-Q 2019-11-19
Q1 2018 -$3.66M -$619K +$7.15M +92% Jan 1, 2018 Mar 31, 2018 10-Q 2019-11-19
Q4 2017 -$10.8M $1.77M +$2.51M Oct 1, 2017 Dec 31, 2017 10-K 2019-04-15
Q3 2017 -$13.3M -$6.67M -$4.45M -201% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-13
Q2 2017 -$8.87M $1.86M +$3.31M Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-13
Q1 2017 -$12.2M -$7.76M -$6.86M -759% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-18
Q4 2016 -$5.32M -$740K +$3.71M +83.4% Oct 1, 2016 Dec 31, 2016 10-K 2018-04-06
Q3 2016 -$9.02M -$2.22M -$938K -73.2% Jul 1, 2016 Sep 30, 2016 10-Q/A 2017-11-09
Q2 2016 -$8.08M -$1.45M -$896K -161% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-10
Q1 2016 -$7.19M -$903K -$423K -88.2% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-12
Q4 2015 -$6.77M -$4.45M -$4.22M -1895% Oct 1, 2015 Dec 31, 2015 10-K 2017-04-17
Q3 2015 -$2.54M -$1.28M -$1.38M -1454% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-14
Q2 2015 -$1.17M -$558K -$355K -175% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-12
Q1 2015 -$811K -$480K +$148K +23.6% Jan 1, 2015 Mar 31, 2015 10-Q/A 2016-05-27
Q4 2014 -$959K -$223K +$452K +66.9% Oct 1, 2014 Dec 31, 2014 10-K/A 2016-05-17
Q3 2014 -$1.41M $94.6K +$547K Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-23
Q2 2014 -$1.96M -$203K +$437K +68.3% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-19
Q1 2014 -$2.4M -$629K +$497K +44.2% Jan 1, 2014 Mar 31, 2014 10-Q/A 2015-06-15
Q4 2013 -$2.89M -$674K -$14.2K -2.15% Oct 1, 2013 Dec 31, 2013 10-Q/A 2015-06-15
Q3 2013 -$2.88M -$452K -$59.5K -15.1% Jul 1, 2013 Sep 30, 2013 10-Q 2013-12-18
Q2 2013 -$2.82M -$640K -$209K -48.6% Apr 1, 2013 Jun 30, 2013 10-Q/A 2013-08-28
Q1 2013 -$2.61M -$1.13M -$695K -161% Jan 1, 2013 Mar 31, 2013 10-Q/A 2013-06-21
Q4 2012 -$1.91M -$660K -$134K -25.5% Oct 1, 2012 Dec 31, 2012 10-K/A 2013-05-03
Q3 2012 -$1.78M -$393K Jul 1, 2012 Sep 30, 2012 10-Q 2013-12-18
Q2 2012 -$431K Apr 1, 2012 Jun 30, 2012 10-Q/A 2013-08-28
Q1 2012 -$431K -$431K Jan 1, 2012 Mar 31, 2012 10-Q/A 2013-06-21
Q4 2011 -$526K Sep 1, 2011 Dec 31, 2011 10-K/A 2013-05-03
Q1 2011 $0 Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-21
* An asterisk sign (*) next to the value indicates that the value is likely invalid.